Three Chinese TIL Therapy Companies Accelerate Clinical Development and Regulatory Progress
Grit Biotherapeutics
Developer of Immunotherapy Drugs for Solid Tumors
HUASAIBIO
Developer of Stem Cell Therapy Products
Juncell Therapeutics
Solid Tumor Cell Therapy Developer
April 1, 2026
eMedClub News
Gravel Biotech
March 31,GT201 Injection Receives FDA Fast Track Designation, for recurrent or metastatic squamous cell carcinoma of the head and neck（HNSCC）Indications. This is its independently developedThe World's FirstMembrane-bound IL-15 Complex Edited TIL Therapy, by StaViral® After editing and modification of the virus stable transfection platform, high expression of IL-15 on the surface of TIL cells can enhance the tumor-killing function of T cells and achieve longer-lasting tumor control by promoting the formation of memory T cells.
On March 28, the new IND application for Grail Bio's GT201 Injection was accepted by the CDE. Currently, GT201 has been approved for IND in both China and the United States, and has entered Phase I clinical research.
Sino-cell Biomed
On March 30, Sino-cell Biomed announced its team's appearance at the Bio-Europe 2026 Spring Summit, interpreting the advantages and clinical progress of two generations of TIL products.
Its first-generation FAST-TIL relies on PowerTexp® Platform,Achieve 14-Day Rapid PreparationFully enclosed automated production, low material sourcing threshold, significantly reduced cost, with excellent clinical efficacy and safety; Second-generation NICE-TILIterative upgrades in innovative design, technology, and targeting, improving clinical accessibility.
Juncell Therapeutics
On March 25, Juncell Therapeutics announced the official release of "Autologous Natural Tumor-Infiltrating Lymphocyte Injection" at the 2026 European Lung Cancer Conference.（GC101）Treatment of Advanced Non-Small Cell Lung Cancer（NSCLC）Phase Ib Clinical Trial（MIZAR-005）"Research plan, and based on the results of Phase IbOfficially Advance to Phase II Clinical Trials。
GC101 isThe World's FirstInnovative Natural TIL Therapy Without Intensive Lymphodepletion Chemotherapy or IL-2 Administration: Clinical Studies Have Shown That GC101 Has Brought Long-Term Benefits to Patients with Advanced Metastatic Solid Tumors Who Failed Multiple Lines of Treatment.
In just a few days, significant new progress has been made in China in various aspects of TIL therapy, including clinical advancements, regulatory submissions, and technical exchanges, further validating the accelerated development of the TIL field.
Exciting Events
Long press to scan the QR code and participate immediately ↓
DianDian "Share”、“Like" and "In View”
Give me a little recharge~